Providing hope to patients with cancer
Harnessing cutting edge science to improve patients lives
Percheron Therapeutics is a clinical-stage biotechnology company advancing first-in-class immuno-oncology therapies to tackle some of the most difficult-to-treat cancers.
A welcome from our MD & CEO
Your dedicated resource for staying informed and engaged with our journey.
As we advance our lead asset, HMBD-002, for the treatment of various cancers, we are committed to keeping investors updated with the latest trial milestones, market insights, and corporate progress.
Visit our website for easy access to key announcements, reports, and to learn about opportunities to connect with our team.
We value your support and look forward to sharing our growth and success with you.
Thank you for being part of Percheron Therapeutics’ Journey.
How HMBD-002 works
Immuno-Oncology
One of the key advances in cancer over recent decades has been the understanding of how a growing tumour interacts with the body’s immune system.
- T cell
- Suppressed T cell
- Tumour cells
- MDSC (myeloid-derived suppressor cell)
- TAM (tumour-associated macrophage)
- VISTA
- HMBD-002 (VISTA antibody)
Ordinarily, our immune system protects us against pre-cancerous cells, in much the same way that it protects against infection.
Monoclonal Antibodies
HMBD-002 is a member of class of drugs known as monoclonal antibodies. Like the antibodies that are produced by our own immune system, monoclonal antibodies allow very specific targeting of pathological cells. Instead of targeting bacteria, for example, monoclonal antibodies can be designed to target cancer cells or, in the case of HMBD-002, to target the signaling between cancer cells and immune cells.
- VISTA
- Light chains
- Stem
Development of HMBD-002
HMBD-002 is well-advanced in clinical development.
HMBD-002 was discovered by Hummingbird Bioscience, one of the world’s most innovative companies in the field of monoclonal antibody drug development.
HMBD-002 has shown activity in a wide range of animal models of cancer, and has shown evidence of synergy when combined with other immuno-oncology drugs such as Keytruda® (pembrolizumab).
Our commitment
At Percheron our commitment goes beyond the science of novel therapies, and we are determined to engage constructively with patients and advocacy organisations.
Compassionate Use and Expanded Access Policy
For investors
Investor centre
Featured announcements
Share price
Current price
Volume
Market Cap.
Year low - high
Market data chart (ASX:PER)
Volume traded
Share price ()
Last price
Open price
Day low - high
Price change
Percentage change
Previous close
Volume (no. of shares)
Turnover
Market cap
Shares outstanding
VWAP
Bid / Ask
52 week high
52 week low
Price/earnings ratio
Earnings per share
Join our Journey
Your dedicated resource for staying informed and engaged with our journey.